I am not pumping or touting this stock but I would like to call your attention to it as I think it may be early in a very long game. The theme here is Diabetes. I know not how big a problem it is in Canada, but in the U.S. it is probably the largest destroyer of healthcare $$$s. Maybe because of obesity its incidence and complications are on the rise. The N.Y.Times just ran a 4 part front page series on it. NXXI markets chromium picolinate, CP,(as Chromax). Chromium is an essential nutritional supplement that apparently plays an important role in glucose utilization. CP has been shown to increase one's sensitivity to Insulin. Now, this should be of some interest to you guys/gals North of The Border, because it was a Canadian team lead by Banting and Best that won a Nobel prize early in the 20th century for discovering Insulin's role in Diabetes. Late last year the FDA gave the company the right to advertise(label)its CP as probably able to help prevent insensitivity to insulin. The >50% rise in the stock yesterday was because the company has morphed from a wholesale distributor of CP to now begin selling it in retail outlets. I have held this while it has swung between $0.40 and $1.40 over the last year or so. CP sales to date have been flat, despite the research results. The company is currently without a CEO. The last CEO was fired because of some hanky panky related to the firing of a member of the management team. Before her departure she had high hopes that CP sales would one day approach those of calcium supplements....What happens next with the stock will depend, imho, on the sales figures for the just ended quarter and the next few quarters. After the huge runup yesterday I would not be a buyer now. But, what do I know?? Please construe this post as a "heads up".....do your own research. .....comments, criticisms welcomed......Missash
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings